Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.70, $0.38 better than the analyst estimate of $0.32. Revenue for the quarter came in at $141.8 million versus the consensus estimate of $133.68 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2025 revenue of $545-565 million, versus the consensus of $558 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.